Literature DB >> 15710855

Prevalence of ulnar neuropathy in patients receiving hemodialysis.

Rachel Nardin1, Kristine M Chapman, Elizabeth M Raynor.   

Abstract

BACKGROUND: Ulnar neuropathy can cause pain, weakness, and sensory changes in the hand and can result in functional impairment. Patients with end-stage renal disease receiving hemodialysis may be predisposed to ulnar neuropathy by factors such as arm positioning during hemodialysis, underlying polyneuropathy, and upper extremity vascular access.
OBJECTIVE: To determine the prevalence of clinically evident ulnar neuropathy in a cohort of 102 patients with end-stage renal disease receiving hemodialysis.
DESIGN: All eligible patients in a single dialysis unit were screened for symptoms and signs of ulnar neuropathy. Those with at least 1 symptom or sign underwent nerve conduction studies to confirm the presence of ulnar neuropathy.
RESULTS: Clinically evident, electrophysiologically confirmed ulnar neuropathy was present in 37 (51%) of the 73 subjects with both screening and nerve conduction study data available. The true prevalence of ulnar neuropathy in this cohort was estimated between 41% and 60%.
CONCLUSIONS: There is a high prevalence of ulnar neuropathy in patients with end-stage renal disease receiving hemodialysis, which has not been previously recognized. The high prevalence of ulnar neuropathy in this population suggests that preventative efforts are indicated to prevent this functionally limiting complication.

Entities:  

Mesh:

Year:  2005        PMID: 15710855     DOI: 10.1001/archneur.62.2.271

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  2 in total

1.  Evaluation of Ulnar neuropathy on hemodialysis patients.

Authors:  Babak Vahdatpour; Razieh Maghroori; Mojgan Mortazavi; Saeid Khosrawi
Journal:  J Res Med Sci       Date:  2012-10       Impact factor: 1.852

2.  Smoking is associated with ulnar nerve entrapment: a birth cohort study.

Authors:  Sina Hulkkonen; Juha Auvinen; Jouko Miettunen; Jaro Karppinen; Jorma Ryhänen
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.